Revenue Grows 37%, But the ₹1,350 Crore Margin Gap Says Wait
OneSource delivered strong topline growth (₹449 Cr, +37% YoY) on semaglutide demand, but operating margins stayed flat at 26.5% against a 40% FY28 target. Management reaffirmed $400M guidance, but execution risk on three pending line ramps and margin recovery timing is substantial.
₹449 Cr
+37.2% YoY; validates semaglutide + new customer wins
26.5% vs. 40%
1,350 bps gap; capex opex upfronted today
~₹123 Cr
+39% YoY; margin leverage deferred to FY28
₹25 Cr
+13,539% YoY; base effect. 5.5% NPM is modest.
The core tension: growth is real, margins are not yet
OneSource's Q1 result is two stories. On revenue, the company delivered: ₹449 Cr, up 37.2% YoY, driven by semaglutide adoption (150K–160K pens/month in India, up from 1,350 basis points behind. Management flagged why: capex-related opex is upfronted today across all three new DDC lines now under construction. Margin recovery is deferred until the lines go live and start absorbing fixed costs. In short: revenue is the floor; margins are a promise.
Our first phase of the US$100 million capex, which we have put in our capex, is now reaching fruition with our second cartridge line being set for commercialization in this quarter… the optimal EBITDA contribution is expected when all lines are live.
Where the numbers came from
Net profit of ₹25 Cr (5.5% NPM) is real but modest. The 13,539% YoY growth is optics—it reflects a tiny Q1 FY26 base, not explosive earnings. Revenue growth of 37% is the honest metric. On EBITDA, management claimed 27.4% margin (implied ₹1,233 Cr from ₹4,490 Cr revenue). The delivered operating profit margin is 26.5%, implying ~₹1,191 Cr EBITDA—a ₹42 Cr (3.5%) gap, likely a depreciation treatment difference and immaterial.
Revenue ₹449 Cr, 37% YoY; EBITDA ₹1,233 Cr, 39% YoY
Revenue verified. EBITDA claimed 27.4% vs. OPM delivered 26.5%; 3.5% variance likely depreciation add-back.
Supported (minor variance immaterial)
>40% of India generic semaglutide pens manufactured at our site
MD specific, customer day-one launches confirmed. Market size <2K to 160K pens/month YoY growth validates scale.
Supported
$400M FY28 revenue achievable with clear order book visibility
Q1 annualized run-rate ~₹1,800 Cr vs. $400M (~₹3,300 Cr target). Requires 83% growth. Order book claimed 'visible' but not quantified.
Mixed (credible direction, execution-heavy)
DDC line 1 at full contribution; optimal EBITDA leverage deferred
Revenue-wise full, EBITDA-wise not due to upfronted capex opex. Transparent disclosure.
Supported (honest on timing)
What changed on this call
Formycon biosimilar partnership named. Previously management mentioned a biologics pipeline; this quarter they announced a concrete win with Formycon (a large global biosimilar player). Still pre-commercial (MSA stage, revenue FY29+), but it moves from potential to named. Soft gelatin CDMO services now core. Under Strides, this was captive IP-led. Now OneSource positions it as CDMO services to European customers. Capacity is 2.4B units; tech transfers underway, but full utilization is 12–15 months away (slower than prior expectations). DDC line roadmap reaffirmed. Lines 2, 3, 4 scheduled Q2 FY27, end-FY27, and FY28 respectively. No upgrades to guidance, but timeline is transparent. The $400M target is reaffirmed, not raised.
Revenue growth 37% YoY on semaglutide demand + new customer wins validates thesis
$400M FY28 target backed by order book + clear line roadmap (lines 2, 3, 4 scheduled Q2–FY28)
Multiple new revenue streams (soft gel CDMO, biologics, injectables) diversify concentration
Management transparent: capex opex upfronted, margin recovery FY28+. Not defensive.
OPM flat at 26.5% vs. 40% FY28 target (1,350 bps gap); expansion timing uncertain
Q1 run-rate ₹1,800 Cr annualized vs. $400M (₹3,300 Cr) target; requires 83% growth
Soft gel CDMO ramp now 12–15 months to full utilization; greenfield adds 2–3 year lead time
Biologics pre-commercial (MSA stage); FY29+ revenue at risk
Customer concentration undisclosed; unnamed major dependencies create concentration risk
PAT ₹25 Cr (5.5% NPM) modest; headline 13,539% YoY growth driven by tiny base
Margin expansion timing (1,350 bps to FY28 target)
HighIf line ramps slip or soft gel adoption lags, margin recovery cascades into FY29+. Q1 flat margin despite 37% revenue growth signals leverage is deferred.
DDC line execution delays (3 lines by FY28)
HighEach line adds ~225 sterile days/year. Any 6-month slip reduces FY28 capacity, impacting the $400M target.
Soft gel tech transfer slowdown
MediumNow 12–15 months to full utilization vs. prior expectations. Greenfield expansion (2–3 year lead) may not meet new customer demand on FY28 timeline.
Biologics commercialization delay (FY29+ assumption)
HighLong-term growth pillar. Currently pre-commercial (MSA stage). Regulatory delays, manufacturing scale-up, or adoption shortfalls push revenue.
Unnamed major customer concentration
MediumLoss of any top customer (Dr. Reddy's implied major, others unnamed) materially impacts $400M target.
Semaglutide demand plateau or price compression
MediumCurrently supply-constrained, but generic competition and market maturity could cool momentum.
How the Street is positioned
The stock opened at ₹1,649 pre-result and popped 2.42% on day 1 (44.5% delivery for the result, indicating institutional uptake). By day 3, the pop had extended to +6.11%, but faded sharply: by day 5, the stock was down 1.78% from the pre-result close. That arc—initial enthusiasm, then fade—suggests the Street is taking a 'show me on execution' stance. The stock trades at ₹1,619.7, down 15.86% from its all-time high of ₹1,925 but up 53.24% from its 52-week low. It sits below both the 20-day and 50-day moving averages (₹1,660 and ₹1,685) but above the 200-day average (₹1,615). RSI of 43.8 is neutral. On flows: FII ownership declined QoQ (from 19.24% to 17.50%, −174 bps), while DII ownership rose (from 18.81% to 20.61%, +180 bps). Foreign investors are trimming; domestic investors are adding. Bulk block data shows mixed activity around ₹1,530–₹1,556 with no obvious insider selling near the all-time high. The Street's 6-day fade after a promising result is consistent with the execution bear case—concentration risk, margin timing, three moving parts ahead.
1 · Q2 FY27 – Line 2 commissioning confirmed
DDC line 2 scheduled to go live in Q2 (the current quarter, ending September 2026). This is the first concrete test of the line ramp timeline. Revenue impact will be modest (another ~225 sterile days/year), but it proves execution capability and de-risks lines 3 and 4.
2 · Q3–Q4 FY27 sequential margin inflection
Watch OPM progression closely. Q1 is 26.5%. If Q2 shows flat or lower OPM despite line 2 going live, operating leverage is at risk. Margin expansion should start showing by Q3 as capex opex burdens are absorbed. OPM trending toward 28–30% by Q3 confirms the FY28 thesis is de-risking.
3 · Soft gelatin utilization and biologics commercial launches
Soft gelatin CDMO claimed to reach full utilization (2.4B units) in 12–15 months (H1 FY28). Watch quarterly soft gelatin revenue; if still below ₹150 Cr/quarter, utilization is lagging. For biologics, look for first commercial product revenue (not just MSA). If Formycon stays pre-commercial through Q4 FY27, FY29 commercialization is at risk.
OneSource is executing a step-change, not steady-state. Q1 validated semaglutide demand (37% growth), but the company is now pivoting from single-line DDC to multi-line + CDMO + biologics partnerships, all in parallel, all critical to hitting $400M FY28. This is execution risk, not demand risk.
Management is transparent; Q&A was substantive. But the Street's 6-day fade (pop to +6.11%, then −1.78% by day 5) is telling: investors are correctly adopting a 'prove it' stance. Margin expansion of 1,350 bps in 7 quarters is ambitious; any slip cascades.
For a holder, the single number to track is OPM progression. Q1 is 26.5%. If Q2 shows flat or lower OPM despite line 2 going live, the operating leverage thesis is in trouble and FY28 margins are at risk. If Q3 shows OPM trending toward 28–30%, the guidance is de-risking. Hold for now; upgrade only after Q2 EBITDA inflection is confirmed.
Informational and educational content only. Not investment advice.